24 results about "Mammalian tissue" patented technology

Microneedle patches that include a backing layer, and an array of microneedles extending from the backing layer. wherein the microneedles each include a core portion which includes a drug, and a shell portion and a cap portion, wherein the core portion is encapsulated within the shell portion and cap portion. The microneedles are configured to be inserted into mammalian tissue and then separate from the backing layer. The shell portion and / or the cap portion is biodegradable and delays release of the drug for an extended period.

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and / or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following:or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

The invention provides novel methods for analyzing (e.g., imaging) drugs in mammalian tissues, and methods for identifying drug targets and analyzing drug-target interactions.

The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue via 18F-labeled peptide ligands disclosed herein.

Described herein are systems, methods, and interconnecting porous hydrogel blocks for generating mammalian tissue. A block may comprise a three-dimensional continuous polymeric matrix with a network of microporous cavities, and may be configured to interconnect with at least one other block. A system may comprise a plurality of blocks configured to interconnect to form a scaffold configured to cultivate one or more cell types organized into stratified layers. A method may comprise acquiring a plurality of blocks, interconnecting the blocks to form a scaffold configured to cultivate one or more cell types organized into stratified layers, and seeding at least one block with at least one cell type adherent to the block. Embodiments may comprise perfusing at least one block with culture media and / or harvesting mammalian tissue generated.

Aspects and embodiments relate to a tissue mimicking material, a clinical phantom including a tissue mimicking material and a method of manufacture of a tissue mimicking material. According to one aspect there is provided: a tissue mimicking material comprising: an alginate matrix; and an ablation-sensitive agent distributed through the alginate matrix. Aspects and embodiments recognise that use of an alginate matrix as a base for a tissue mimicking material provides relatively low cost material having various physical properties and characteristics which can be tuned or refined to simulate the characteristics of a mammalian tissue which the alginate matrix is intended to mimic. In relation to use of an alginate material in the context of thermal and / or pulsed electric field ablation simulation, it has been recognised that an alginate material may be appropriately temperature stable and not degrade upon exposure to high, or low, ablation temperatures, or upon exposure to ablation levels of pulsed electric field. Distribution of an appropriately selected ablation-sensitive agent through the alginate material may allow a change caused by application of an ablation technique to the tissue mimicking material to be observed.

A method of sterilizing biological tissue such as soft mammalian tissue that can be used to make bioprosthetic devices is disclosed. The method comprises contacting biological tissue with a bioburden reduction mixture, contacting biological tissue with a tissue drying mixture, and thereafter sterilizing the dry tissue with supercritical carbon dioxide. Prior to sterilizing the biological tissue with supercritical carbon dioxide, the biological tissue is placed under vacuum and, in some embodiments, is treated with a vaporized microbicide. Bioprosthetic devices made using the methods disclosed herein include bioprosthetic heart valves, biological tissue derived vascular grafts or vessels, and surgical tissue patches.

Provided is use of a protein synthesis inhibitor in promoting regeneration and repair capacity of mammal tissues or complex structures or organs. The protein synthesis inhibitor is a small molecule compound, from any of cycloheximide or an Amaryllidaceae extract, capable of promoting regeneration of mammal tissues and organs.

There is provided a liquid injection device (10) comprising an injection tube (12), wherein the injection tube (12) extends in a hollow tip (14) with a plurality of openings (16). At least three circumferentially displaced openings (16) are provided around the hollow tip (14) below an edge (15) of the hollow tip (14) and the hollow tip (14) is provided with a non-cutting edge. There is also provided a method for performing heat therapy of mammalian tissue, comprising the steps: inserting an injection tube (12) extending in a hollow tip (14) in a selected position in the tissue, injecting a liquid including at least one anesthetic and adrenaline heated to a temperature of at least 37° C through the injection tube and through a plurality of openings (16) 0 below an edge (15) of the hollow tip (14) into the mammalian tissue.

Compositions and methods for providing the hybrid benefit of treating biofilms on the surface of mammalian tissue, especially biofilms that occur in association with chronic wounds and burns, and simultaneously providing an antiseptic cleansing and maintenance of the stratum corneum of the tissue and other tissue surfaces, and an opportunity for the tissue to improve by engaging its own natural barrier and immunological defense properties. The compositions and methods prevent the re-establishment of biofilms by facilitating the reduction or eradication of the pathogen producing the biofilm before the biofilm can be established.

A thermally representative phantom mammalian manikin assembly is provided. The assembly can include a cover portion representative of mammalian tissue partially enclosing a thermal cavity having a thermally representative material therein. The cover portion can have an opening with a cap extending across the opening and configured to further enclose the thermal cavity. The cap can have an aperture extending therethrough to receive a device extending through the aperture and into the thermally representative material within the thermal cavity. The device can be a thermocouple configured to measure a temperature of the thermally representative material. In assemblies representing mammalian limbs, the assembly can further include a second thermal cavity representing an additional portion of the limb, e.g., thermally representative upper and lower leg cavities.

Provided herein are compounds useful for inducing biostasis. Also provided are pharmaceutical compositions comprising the compounds, kits comprising the compounds, methods of inducing biostasis in subjects, biological samples and cells, and methods of preserving biological samples (e.g., mammalian tissue) by a compound or composition described herein.

1. The name of the product under this design: stapler. 2. Application of the product with this design: It is used for internal suturing of mammalian tissues, and is particularly suitable for internal suturing of human tissues during minimally invasive or non-invasive surgery. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: a three-dimensional diagram of the combined state. 5. Other situations that require explanation: Component description: Component 1 is a suture needle, and component 2 is a suture device without a suture needle.

A liquid injection device may include an injection tube. The injection tube may extend to a hollow tip with a plurality of openings. At least three circumferentially displaced openings may be provided around the hollow tip below an edge of the hollow tip, and the hollow tip may be provided with a non-cutting edge. A method for performing heat therapy of mammalian tissue may involve inserting an injection tube extending to a hollow tip in a selected position in the tissue. A liquid including at least one anesthetic and adrenaline heated to a temperature of at least 37° C. may be injected through the injection tube and through a plurality of openings below an edge of the hollow tip into the mammalian tissue.

A brachytherapy composition fabricated from mammalian tissue is provided. Methods of processing a mammal's mammalian tissue to form a brachytherapy composition are provided. Regenerative methods are also provided.

Embodiments disclosed include systems, methods, and apparatuses, directed to administering thermal neural modulation to mammalian tissue to control nerve conduction. Embodiments disclosed include an apparatus comprising a thermal energy source, a first heat exchanger coupled to the thermal energy source and configured to receive thermal energy therefrom, a thermal applicator configured to be disposed and secured to the anatomy of a subject having a nerve therein, in contact with the skin on the anatomy and overlying a treatment portion of the nerve, the thermal applicator configured to transfer thermal energy to the skin to raise the temperature of the treatment portion of the nerve above a physiologic temperature, a second heat exchanger is coupled to the thermal applicator and configured to transfer thermal energy thereto, and a fluid conduit having a first portion coupled to the first heat exchanger and a second portion coupled to the second heat exchanger. The fluid conduit is configured to have fluid circulated therethrough to convey thermal energy from the thermal energy source via the first heat exchanger and to the thermal applicator via the second energy at a temperature.

The disclosure provides an antimicrobial composition comprising hypohalous acid and a salt of an organic acid, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, and other uses.

Prosthetic heart valves having a conical shaped base valve structure formed from collagenous mammalian tissue and an expandable stent structure. The base valve structure includes a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, wherein the elongated ribbon members are positioned adjacent each other and form a plurality of fluid flow modulating regions that open when fluid into and through the base valve structure exhibits a positive pressure relative to the exterior pressure, i.e., a positive pressure differential, wherein the fluid is allowed to be transmitted out of the base valve structure, and transition to a closed configuration when the pressure differential between the interior valve pressure and exterior pressure reduces, wherein the fluid is restricted from flowing out of the base valve structure. The expandable stent structure includes a plurality of tethers adapted to pierce cardiovascular tissue and, thereby, position the base valve structure and, thereby, prosthetic valves formed therewith on said heart valve annulus.

Disclosed herein is an improved examination method for examining a fluorescence image taken of mammalian tissue treated with a fluorescent agent to be photosensitive and irradiated with excitation light, the fluorescence image (FI) comprising an array of pixels having respective fluorescence signal values, the fluorescence signal values include fluorescence signal values representing a first quantity (N1) of mammalian tissue in the fluorescence image. The improved inspection method comprises: determining (S6) a reference value (IR) such that a second number (N2) of fluorescence signal values contained in a first number of fluorescence signal values is less than or equal to said reference value and the remainder of the first number of fluorescence signal values exceeds said reference value, said second number being a predetermined fraction of said first number; determining (S7) an average fluorescence signal value ([mu] R) and a standard deviation ([sigma] R) of fluorescence signal values contained in the second number of fluorescence signal values; performing (S8) image segmentation in the fluorescence image (FI) to distinguish between a target region (TR) representing a portion identified as tumor tissue in the mammalian tissue (MT) and a reference region (RR) representing a remaining portion in the mammalian tissue (MT), including a determination for each pixel (p) and a determination for each pixel (p); determining that the pixel belongs to the target region (TR) if the signal-to-noise ratio CNR (p) of the pixel exceeds a predetermined threshold value (TCNR), otherwise determining that the pixel belongs to the reference region (RR), where the signal-to-noise ratio CNR (p) of the pixel is as defined in (I): (I) # imgabs0 # where FI (p) is the fluorescence signal value of the pixel (p), c is a predetermined constant; at least one contour (B) of the target area (TR) is identified (S9).

Aspect and embodiments relate to a tissue mimicking material, a clinical phantom including a tissue mimicking material and a method of manufacture of a tissue mimicking material. One aspect provides a tissue mimicking material comprising: an elastomeric solid foam. The foam comprises gas pockets dispersed in an elastomeric material matrix and a liquid lubricant arranged within the gas pockets of the elastomeric solid foam. Aspects and embodiments recognise that a self lubricating tissue mimicking material provides a mechanism to emulate particular in vivo mammalian tissues. The modified foam material in accordance with aspects has various physical properties and characteristics which can be tuned or refined to simulate the characteristics of a mammalian tissue which the foam is intended to mimic.

Optical, geometric, and / or physiological characteristics of a mammal and / or a pregnant mammal's abdomen may be used to determine a personalized calibration formula for the respective mammal or pregnant mammal's abdomen. This personalized calibration formula may be used to analyze or evaluate light transmission data corresponding to an optical signal that is detected by a photodetector and converted into the light transmission data to determine an oximetry value for the mammal, pregnant mammal, and / or fetus. The optical signal may be a composite of light that was incident on the mammal or pregnant mammal's abdomen her fetus. On some occasions, an image of the mammal's tissue and / or the pregnant mammal's abdomen may be received and used to generate a tissue model of the respective mammal's tissue or maternal abdomen. The tissue model may be used to generate, or adjust, the personalized calibration formula.

Systems and methods for phototherapeutic modulation of nitric oxide in mammalian tissue include use of a first wavelength and first radiant flux of light to stimulate enzymatic generation of nitric oxide, and use of a second wavelength and second radiant flux of light to stimulate release of nitric oxide from endogenous stores of nitric oxide. Pulsed light and / or partially non-overlapping light impingement windows may be used. Non-coherent light impinged on tissue may include a peak wavelength in a range of from 410 nm to 440 nm in the absence of light emissions having a peak wavelength of from 600 nm to 900 nm.

Provided herein are compounds useful for inducing biostasis. Also provided are pharmaceutical compositions comprising the compounds, kits comprising the compounds, methods of inducing biostasis in subjects, biological samples and cells, and methods of preserving biological samples (e.g., mammalian tissue) by a compound or composition described herein.

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and / or mammalian tissue overexpressing prostate specific membrane antigen ("PSMA") where the compounds are represented by the following Formulas (I), or a pharmaceutically acceptable salt thereof (IA), or a pharmaceutically acceptable salt thereof (II), or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.